What to Know About the USPTO Access to Relevant Prior Art Initiative

The USPTO recently announced its Relevant Prior Art (RPA) Initiative, seeking to leverage electronic resources to improve an examiner’s access to relevant information from applicant’s other related applications.  These resources may include related U.S. applications, international applications under the PCT, and counterpart foreign applications by the same applicant. What are the advantages? Simplifies application process for applicant Speeds up examination process Increases efficiency of prosecution procedures Improves prosecution quality What you should be aware of Notification of application included in RPA initiative.  You will receive a Notice of Imported Citations informing you of your application’s inclusion in the Initiative and

Continue reading »

MaxVal Publishes Advanced CRISPR-Cas9 Report

Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research.  The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research.  The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers. MaxVal’s CRISPR report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract

Continue reading »

Hot Topics in Tech | October 2018 Newsletter | Maxval

This article provides a brief overview of the role of the autonomous nervous system in managing hypertension and describes various techniques related to neurostimulation. Patents revealing various energy-based techniques for neurostimulation, and devices related thereto which are available in the market are also presented. It also highlights various sectors where artificial intelligence (AI) powered robots are employed in, and focuses on two major industries a) agriculture and b) retail. Key players in this technology along with the tech categorization of their patent portfolio are charted out, and some exemplary patents in both agriculture and retail are illustrated.

Continue reading »

MaxVal Releases Next Generation Patent Prosecution and Business Decision Tool, symphony® AI

MaxVal announces symphony® AI, the most advanced patent prosecution tool available on the market. It leverages the Salesforce Lightning architecture to integrate public and private data into a unique solution that provides decision guidance, predictions, and unprecedented insight into clients’ portfolios. symphony® AI’s intelligent analytics module recommends prosecution and portfolio management strategies. It also provides a robust set of dashboards, cost projection tools, and self-service analytics to simplify the portfolio review process and deliver actionable business intelligence across an entire portfolio. symphony® AI is available as part of MaxVal’s symphony® cloud-based platform or as a stand-alone module compatible with any IP

Continue reading »

MaxVal Releases Max-IDS™ 4.0.2

MaxVal announces the latest upgrade to its information disclosure statement software, Max-IDS™, version 4.0.2. This new version includes multiple enhancements and new features, including: Enhanced, high-speed import process for citations and non-patent literature, which eliminates manual effort and thereby reduces data entry errors. New reference aging system helps avoid  Patent Term Adjustment (PTA) delays and supplemental IDS fees. Expanded authentication and integration capabilities simplify deployment, eliminate password complexity for users and enhances connectivity with docketing systems. Updated user-friendly dashboards, reports and alerts ensure users have quick, easy access to critical data needed to ensure timely filing of IDSs. “As a leader

Continue reading »

Hot Topics in Tech | September 2018 Newsletter | Maxval

This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.

Continue reading »

MaxVal Announces symphony® 1.5 – The Latest Version of Its Intellectual Property Management System

MaxVal announces the latest upgrade to its advanced, cloud-based IP management platform, symphony®. Since its launch in 2016, symphony® has revolutionized IP management through its innovative use of Salesforce.com’s Lightning platform, delivering the industry’s most advanced workflow and automation capabilities; all in a highly configurable, intuitive system, designed for the modern IP department. “MaxVal’s symphony® platform delivers a host of innovative and compelling operational capabilities to a yearning IP Management market,” said Eyal Iffergan, President of Hyperion Research, the industry’s leading analyst-based market research firm covering the IPM market. “Symphony harnesses the expansive Salesforce feature toolkit to achieve a robust end-to-end

Continue reading »

Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some insights about the company alongwith a quick run-through of the firm’s recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification. We have also discussed about Walmart, who aims to venture into transportation and logistics markets through a methodology (recently filed for patent) by

Continue reading »

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018. We have

Continue reading »

Technology Landscape Study on CRISPR-Cas9

Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives. The objective of this study is to explore the market and patenting activity in CRISPR-Cas9 gene editing technology. This study considers issued patents and pending published applications related to CRISPR-Cas9 published since January 1, 2007. Search strategies using various combinations of keywords, classification codes, and prominent assignees resulted in more

Continue reading »